{
    "root": "28df79fc-18ef-4bae-b7f1-5ee8fc244666",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "glyburide-metformin hydrochloride",
    "value": "20250306",
    "ingredients": [
        {
            "name": "GLYBURIDE",
            "code": "SX6K58TVWC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5441"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6802"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SAND",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "PEG-135",
            "code": "30IQX730WE"
        },
        {
            "name": "PROPYLENE GLYCOL, (R)-",
            "code": "602HN5L69H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "KI203",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": {
        "text": "glyburide metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adult : \u2022 give glyburide metformin hydrochloride tablets divided doses , twice daily , meals . ( 2.1 ) \u2022 patients treated either glyburide ( another sulfonylurea ) metformin hcl , initiate treatment another formulation dose 1.25 mg glyburide 250mg metformin hcl orally , twice daily meals . ( 2.1 ) \u2022 patients adequately controlled either glyburide ( another sulfonylurea ) metformin hcl alone , recommended starting dose 2.5 mg/500 mg 5 mg/500 mg orally twice daily meals . ( 2.1 ) \u2022 patients previously treated combination therapy glyburide ( another sulfonylurea ) metformin hcl , starting dose exceed daily dose glyburide ( equivalent dose another sulfonylurea ) metformin hcl already taken . ( 2.1 ) \u2022 increase dose gradually basis glycemic control tolerability , maximum maximum dose 20 mg glyburide/2,000 mg metformin hcl daily . ( 2.1 ) renal impairment : prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) ( 2.4 ) patients egfr 30 ml/minute/1.73 2 ( 2.4 ) initiation recommended patients egfr 30 45 ml/minute/1.73 2 ( 2.4 ) assess risk/benefit egfr falls 45 ml/minute/1.73 2 ( 2.4 ) discontinue egfr falls 30 ml/minute/1.73 2 ( 2.4 ) discontinuation iodinated contrast imaging procedures : glyburide metformin hydrochloride tablets may need discontinued time , prior , iodinated contrast imaging procedures ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "product : 50090-7514 ndc : 50090-7514-0 60 tablet bottle ndc : 50090-7514-2 100 tablet bottle ndc : 50090-7514-3 90 tablet bottle ndc : 50090-7514-4 180 tablet bottle",
    "adverseReactions": "glyburide metformin hydrochloride tablets contraindicated patients : \u2022 severe renal impairment ( egfr 30 ml/min/1.73 m2 ) [ ( 5.1 ) ] . \u2022 hypersensitivity metformin glyburide.\u2022 acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma.\u2022 concomitant bosentan [ ( 7 ) ] .",
    "indications_original": "Glyburide and metformin hydrochloride tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications_original": "Adult Dosage: \u2022 Give glyburide and metformin hydrochloride tablets in divided doses, twice daily, with meals. ( 2.1 ) \u2022 For patients not treated with either glyburide (or another sulfonylurea) or metformin HCl, initiate treatment with another formulation with a dose of 1.25 mg glyburide and 250mg metformin HCl orally, once or twice daily with meals. ( 2.1 ) \u2022 For patients not adequately controlled on either glyburide (or another sulfonylurea) or metformin HCl alone, the recommended starting dose is 2.5 mg/500 mg or 5 mg/500 mg orally twice daily with meals. ( 2.1 ) \u2022 For patients previously treated with a combination therapy of glyburide (or another sulfonylurea) and metformin HCl, the starting dose should not exceed the daily dose of glyburide (or equivalent dose of another sulfonylurea) and metformin HCl already being taken. ( 2.1 ) \u2022 Increase the dose gradually on the basis of glycemic control and tolerability, up to a maximum to a maximum dose of 20 mg glyburide/2,000 mg metformin HCl daily. ( 2.1 ) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.4 ) o Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.4 ) o Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 ( 2.4 ) o Assess risk/benefit if eGFR falls below 45 mL/minute/1.73 m 2 ( 2.4 ) o Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.4 ) Discontinuation for Iodinated Contrast Imaging Procedures: o Glyburide and metformin hydrochloride tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures ( 2.5 )",
    "warningsAndPrecautions_original": "Product:    50090-7514\n                  NDC:    50090-7514-0   60 TABLET in a BOTTLE\n                  NDC:    50090-7514-2   100 TABLET in a BOTTLE\n                  NDC:    50090-7514-3   90 TABLET in a BOTTLE\n                  NDC:    50090-7514-4   180 TABLET in a BOTTLE",
    "adverseReactions_original": "Glyburide and metformin hydrochloride tablets is contraindicated in patients with:\u2022 Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1)].\u2022 Hypersensitivity to metformin or glyburide.\u2022 Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.\u2022 Concomitant administration of bosentan [see Drug Interactions (7)].",
    "drug": [
        {
            "name": "glyburide-metformin hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36807"
        }
    ]
}